Compugen to Announce Q1 2024 Results on May 20, 2024

Compugen Ltd., a clinical-stage company specializing in cancer immunotherapy and computational target discovery, has announced the release of its first quarter 2024 financial results. The announcement is set for Monday, May 20, 2024, before the opening of U.S. financial markets. On the same day, the management will hold a conference call and webcast at 8:30 AM ET to discuss the financial results and provide a corporate update.

Interested parties in the U.S. can join the live conference call by dialing 1-866-744-5399, while international participants can dial +972-3-918-0644. Additionally, the call will be broadcast live via webcast on Compugen's website, and a replay will be accessible post-webcast.

Compugen Ltd. is renowned for its innovative approach to therapeutic discovery and development, leveraging predictive computational discovery techniques to identify new drug targets and biological pathways. This methodology has been instrumental in advancing cancer immunotherapies.

The company’s portfolio includes two main product candidates: COM701, an anti-PVRIG antibody poised to be the first in its class, and COM902, an anti-TIGIT antibody that could potentially set a new standard in its category. Both candidates are designed for the treatment of solid tumors.

In partnership with AstraZeneca, Compugen is progressing with rilvegostomig (earlier known as AZD2936), a bispecific antibody that combines PD-1 and TIGIT targeting based on COM902. This compound is currently in Phase 3 development and results from a licensing agreement aimed at creating bispecific and multispecific antibodies.

Furthermore, Compugen's early-stage immuno-oncology pipeline is addressing various immune resistance mechanisms. The most advanced of these programs, COM503, is undergoing IND enabling studies and is licensed to Gilead. COM503 functions by inhibiting the interaction between IL-18 binding protein and IL-18, thereby enhancing the natural anti-cancer effects of IL-18 in the tumor microenvironment.

Compugen is headquartered in Holon, Israel, and maintains an office in San Francisco, CA. Its shares are publicly traded on both Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.